Fintel reports that on June 3, 2025, B. Riley Securities upgraded their outlook for Kymera Therapeutics (NasdaqGM:KYMR) from ...

B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on ...

Riley founded B. Riley in 1997, currently serving as the financial services firm’s co-chief executive and chair. The Sawtelle firm’s stock decreased in value by about 90% as of early May in the wake ...

Now some are questioning whether it can survive. B. Riley’s fortunes changed dramatically after its biggest deal went bad, leading to huge losses, the crash of its stock price — and a ...

The shares have fallen more than 96% since they hit a high of $88.86 at the end of 2021. The firm suspended its dividend last August and came under even more pressure after Franchise Group, the ...

B. Riley Financial, Inc. (Nasdaq: RILY) ("BRF" or the "Company") today announced it received an expected delinquency notification ...

Additionally, B. Riley Financial will issue warrants for about 372,000 common shares at an exercise price of $10.00 per share, which are exercisable over a seven-year term. Chairman and Co-Chief ...

Bank discloses subpoena from the SEC and problems with its exposure to Franchise Group Inc. B. Riley Financial Inc.'s stock lost half its value Monday after the investment bank said it's ...

B. Riley Financial Inc. is facing more scrutiny from authorities, with the company disclosing that the Financial Industry Regulatory Authority is looking into the firm’s wealth management business.

B. Riley analyst Craig Ellis lowered the firm’s price target on Microchip (MCHP) to $60 from $75 and keeps a Buy rating on the shares. The firm reduced second half of 2025 estimates in the auto ...